THY1 and neoplasm: Immunohistochemistry result of CD90 tracking (Figure 2(a)) showed that on day 1 after the administration of AF-MSCs, the AF-MSCs were mostly distributed throughout the periphery of the tumors and could hardly be found in the deep tumor regions.